The APPG on Malaria and Neglected Tropical Diseases is supported by a number of partners who specialise in tackling the burden of malaria and neglected tropical diseases through campaigning, programmes. Supporting partners are listed below and their work contributes to the learnings and inquiries undertaken by the Group. The parliamentary members of the APPG are open to working with new partners in this area, so would welcome organisations approaching us via our Group Secretariat.
Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organisation working to discover, develop, and deliver treatments for neglected patients around the world.
Malaria No More UK’s mission is to catalyse and inspire the global partnerships, leadership, and financing to make malaria no more in a generation. Malaria has been described as one of the oldest killer diseases in history; even now, despite recent progress, it claims the life of a child every two minutes. Malaria No More UK is part of a global movement that is determined to make this the generation that ends this preventable and treatable disease. To realise this vision, Malaria No More UK mobilises governments, influencers, businesses, and the public, inspiring them to commit funds, energy, and resources to ending deaths from malaria and wiping out the disease for good.
PATH's Malaria Vaccine Initiative (MVI) is a program of PATH, an international non-profit organisation that drives transformative innovation to save lives and improve health, especially among women and children. MVI works with partners in private industry, government, and academia to develop malaria vaccines. Activities include:
- Establishing partnerships to manufacture and produce malaria vaccine candidates.
- Evaluating and managing intellectual property issues to overcome or avoid commercial barriers to vaccine development.
- Developing clinical trial sites and conducting malaria vaccine clinical trials.
- Developing and refining vaccine evaluation technologies.
- Advocating around the need for malaria vaccines and around the need to increase global spending for malaria research and development.
MMV is a leading product development partnership (PDP) in antimalarial drug research. MMV and partners manage a portfolio of over 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled. The 2021 portfolio includes eleven compounds in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. Since its foundation in 1999, MMV and partners have developed and brought forward eleven new medicines, with two more added to the portfolio post-approval. The impact of these new antimalarials has been impressive. In total, an estimated 2.7 million lives have been saved by the medicines supported by MMV and partners.
The UK Coalition against Neglected Tropical Diseases (NTDs) is a collaborative partnership between UK organisations actively engaged in the implementation, capacity building and research of NTDs disease control at scale. The UK Coalition against NTDs believes that national government leadership is essential to deliver effective and sustainable NTD control efforts. To improve the coordination and effectiveness of these programmes the Coalition works with its partners to integrate with other health, water and sanitation and education initiatives, where ever possible.
Uniting to Combat Neglected Tropical Diseases is a global advocacy organisation and collective of invested, interested and dedicated partners, including governments, donors, pharmaceutical companies, non-governmental organisations, academia and more working to end NTDs. Their vision is a world where no-one suffers from these preventable and treatable diseases.